Alaunos Therapeutics Inc. has announced a regulatory compliance issue following the voluntary resignation of Mr. Weis from his roles as chairman of the Audit Committee and member of the Compensation Committee. This resignation has resulted in the company's noncompliance with Nasdaq Listing Rule 5605(c), which mandates that the audit committee must consist of at least three independent directors. The company has informed Nasdaq of this material noncompliance and intends to utilize a 180-day grace period, effective from July 2, 2025, to appoint a new member to the Audit Committee and restore compliance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.